Invitae Appoints Dr. David Sholehvar As Chief Operating Officer, Effective November 13, 2023
Portfolio Pulse from Benzinga Newsdesk
Invitae (NYSE:NVTA), a medical genetics company, has appointed Dr. David Sholehvar as its new Chief Operating Officer, effective from November 13, 2023. Dr. Sholehvar has a 25-year track record in healthcare business leadership, having held roles at NeoGenomics Inc., Dynex Technologies, Quest Diagnostics, and Johnson & Johnson. As part of his hiring, Invitae is granting 850,000 restricted stock units to Dr. Sholehvar under its 2015 Stock Incentive Plan.
October 19, 2023 | 8:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The appointment of Dr. David Sholehvar as COO of Invitae could potentially bring positive changes to the company due to his extensive experience in healthcare leadership. The granting of 850,000 restricted stock units to Dr. Sholehvar could also have an impact on the company's stock.
Dr. Sholehvar's extensive experience in healthcare leadership could potentially bring about positive changes in Invitae's operations, which could positively impact the company's performance and, consequently, its stock. The granting of 850,000 restricted stock units to Dr. Sholehvar could also have an impact on the company's stock, as it could potentially dilute the value of existing shares.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100